# A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

> **NCT05714072** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (estimated)

## Conditions studied

- Myelofibrosis Due to and Following Polycythemia Vera

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT05714072
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-25
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05714072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05714072, "A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05714072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*